What Is Leuprolide? Definition and What Research Reports

Leuprolide (most often encountered as leuprolide acetate) is a synthetic peptide analogue of gonadotropin-releasing hormone (GnRH, also called LHRH). It is a nonapeptide — a chain of nine amino acids — built on the natural GnRH decapeptide sequence with substitutions that make it far more resistant to enzymatic breakdown and more potent at the pituitary GnRH receptor than the native hormone. Because it is an agonist, continuous exposure first stimulates and then downregulates pituitary GnRH receptors, which reduces downstream luteinizing hormone (LH), follicle-stimulating hormone (FSH) and sex-steroid output. That two-phase pharmacology — an initial surge followed by suppression — is the single most important thing to understand about how the molecule is described in the literature. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medical treatment.

What Class of Molecule Is It?

Leuprolide belongs to the GnRH agonist class of peptide hormone analogues. Related terms a reader may see alongside it include:

• GnRH / LHRH analogue — the broad family of peptides modelled on the hypothalamic releasing hormone.
• GnRH agonist — molecules such as leuprolide, goserelin and triptorelin that activate the receptor and, with sustained exposure, desensitise it.
• GnRH antagonist — molecules that block the receptor directly without an initial stimulation phase; the oral antagonists relugolix and elagolix appear in head-to-head literature with leuprolide (PMID 38143206, PMID 30724096).
• Depot formulation — a sustained-release injectable or implantable preparation; a 2023 review in F&S Reports traced the clinical development of leuprolide acetate depot formulations and their role in reproductive medicine (PMID 37223757).

Where It Comes From

Leuprolide is not extracted from tissue; it is chemically synthesised, typically by solid-phase peptide synthesis, and is supplied as the acetate salt. Its short peptide length makes it a convenient scaffold for chemists who want to attach other groups to a GnRH-receptor-targeting backbone. Researchers have, for example, synthesised and radiolabelled a leuprolide peptide analogue with gallium-68 and lutetium-177 and evaluated it preclinically as a candidate imaging agent for GnRH-receptor-expressing breast cancer (PMID 35325547). That kind of work illustrates the molecule's second research identity: not only a hormone-suppressing drug, but a targeting ligand.

How the Term Is Used in Peptide Research

In the published literature, "leuprolide" is used in several distinct ways, and readers encountering the word out of context often conflate them:

What the Published Literature Reports

Prostate cancer and testosterone recovery

Leuprolide has served for decades as the reference GnRH agonist in androgen-deprivation research. A 2024 analysis of the phase 3 HERO study reported that testosterone recovery after discontinuation differed between men who had received the oral GnRH antagonist relugolix and those who had received leuprolide, with faster recovery in the relugolix arm (PMID 38143206). In a separate 2026 post hoc analysis of the EMBARK trial, researchers examined enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer and reported outcomes broken out by age group (PMID 41274168). Both illustrate how the molecule functions as a benchmark rather than a novelty in oncology literature.

Gynecology and fertility

A 2012 randomised trial in The New England Journal of Medicine compared 13 weeks of oral ulipristal acetate with leuprolide acetate depot injections in women with symptomatic uterine fibroids and reported that ulipristal was noninferior for control of uterine bleeding, while moderate-to-severe hot flushes were reported more frequently in the leuprolide group (PMID 22296076). A 2019 US economic analysis modelled elagolix against leuprolide acetate for moderate-to-severe endometriosis pain and reported cost-effectiveness estimates favouring the oral antagonist (PMID 30724096). In oncofertility, a 2023 study of adolescents undergoing gonadotoxic therapy reported that leuprolide was associated with protection of ovarian reserve (PMID 36976803).

Pediatric endocrinology and diagnostic testing

Beyond treatment, leuprolide appears as a diagnostic stimulus. A 2020 pediatric study assessed the utility and optimal sampling duration of leuprolide stimulation testing in children being evaluated for central precocious puberty (PMID 32692703). A 2023 report in Transgender Health examined QTc interval measurements in gender-diverse youth receiving leuprolide acetate (PMID 36895314).

Preclinical work outside endocrinology

Some animal literature has explored effects that are not obviously hormonal. A 2015 rat study reported that leuprolide acetate administration was followed by structural and functional recovery of the injured spinal cord (PMID 26807118). Findings of this kind are preclinical, single-model results and have not been established in humans; the study describes an animal observation, not a clinical outcome.

Adverse Events in the Literature: What Studies Report

Because leuprolide suppresses sex-steroid production, much of the tolerability literature concerns hypogonadal symptoms. In the fibroid trial described above, researchers reported moderate-to-severe hot flushes more often among participants receiving leuprolide acetate than among those receiving ulipristal acetate (PMID 22296076). Case-level reports document less common events: a 2020 case report described pseudotumor cerebri in a patient receiving leuprolide acetate for central precocious puberty (PMID 33292495), and a 2014 dermatology report described a generalized papular eruption attributed to leuprolide acetate (PMID 24918569). Cardiac repolarisation has also been studied, with a 2023 report evaluating QTc intervals in gender-diverse youth on leuprolide acetate (PMID 36895314). Single case reports describe what happened in one patient and cannot establish how often an event occurs.

Limits of What the Evidence Can Say

Several caveats apply when reading about this molecule. First, indication matters enormously: results from prostate cancer trials in older men (PMID 41274168) do not transfer to pediatric endocrinology or fertility preservation (PMID 36976803). Second, formulation and release kinetics differ substantially across depot products, which the 2023 development review discussed (PMID 37223757). Third, economic models such as the endometriosis analysis depend on assumptions and pricing inputs specific to a country and year (PMID 30724096). Finally, leuprolide is a prescription pharmaceutical in the jurisdictions where it is approved, not a research-use-only research peptide, and the literature summarised here describes supervised clinical and laboratory settings.

This glossary entry defines the term and summarises what published studies reported. It does not describe or suggest any protocol, and it is not a substitute for individual medical evaluation.

References

• Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study (European Urology Oncology, 2024)
• Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age (European Journal of Cancer, 2026)
• Ulipristal acetate versus leuprolide acetate for uterine fibroids (The New England Journal of Medicine, 2012)
• Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA (Journal of Comparative Effectiveness Research, 2019)
• Leuprolide Protects Ovarian Reserve in Adolescents Undergoing Gonadotoxic Therapy (Journal of Adolescent and Young Adult Oncology, 2023)
• Clinical development of the GnRH agonist leuprolide acetate depot (F&S Reports, 2023)
• Utility and duration of leuprolide stimulation testing in children (Journal of Pediatric Endocrinology & Metabolism, 2020)
• Leuprolide Acetate and QTc Interval in Gender-Diverse Youth (Transgender Health, 2023)
• Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty (International Journal of Pediatric Endocrinology, 2020)
• Leuprolide acetate-induced generalized papular eruption (Journal of Drugs in Dermatology, 2014)
• Leuprolide acetate induces structural and functional recovery of injured spinal cord in rats (Neural Regeneration Research, 2015)
• Synthesis, Radiolabeling, and Preclinical Evaluation of 68Ga/177Lu-Labeled Leuprolide Peptide Analog for the Detection of Breast Cancer (Cancer Biotherapy & Radiopharmaceuticals, 2022)